Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Me too.
I get frustrated too with ENZC management mistakes. I like the stock, but can acknowledge errors.
Understand though, human beings all err, even Bulgarian posters. Even I do; we are all flawed human beings. CEO's all err, too: Bill Gates just advocated for people to eat fake meat (yuck!). Zuckerberg was just chastised for helping cheat in an election. Elon Musk is being investigated by the SEC for tweeting.
Let's stipulate that the ENZC management team has made some (rookie?) mistakes: the PR strategy has been odd in the past, some tweeting is out of place, they are (sometimes) putting time frames where they do not need to and then when they miss a target, open themselves up for criticism. Prior to the merger with BioClonetics, there was much flailing around because the company was under financed. And, I will also stipulate that the ENZC management team will goof up some more - like every other CEO, like we all will - human beings are all flawed.
But just like with the hour-by-hour technical/pricing analysis: WHO CARES?
ENZC may be sitting on world-changing drugs and AI and other technology. If all these things fail, the price of $0.08 is wildly overpriced and everyone will lose out. But, if any one of these things hit, $0.08 is an absolute bargain, we will be looking at a massive improvement in price.
That's the nature of drug development companies. It's kind of a lotto ticket, but it's not all chance.
All this discussion of: dilutionfloatstinkypinkyTRASHfoodsupplementREDFLAGdumpingscammingpumpanddump
ad nauseam is tiresome, because it doesn't matter to the bigger picture. Yes, there has been an increase in the float (there has been no dilution, though)...and the price still went up 80,000%. Because it doesn't matter. The only thing that matters is:
Are the ENZC initiatives going to work? The fact is that no one knows for sure, it's probability.
When ITV-1 becomes successful, or the IPF spray or the AI, or the MS drug, or the monoclonals, etc. all the little stuff will not matter and the stock price will skyrocket.
Progress on ITV-1 is irrefutable
(Success is not guaranteed, though.) But, wow, those scammers who are suing ENZC must also know that there's something there, or they would not bother to spend money on attorneys.
Smart investors should note that this post does not engage with the ITV-1 discussion. (though those posts are good at "cut-and-paste yelling"...;)
Notice how posts of this ilk rarely engage with the tangible, and significantly more interesting(!) points around the science and the marketing around the various IP of ENZC. 20 patents, (including that one I had missed on MS), the AI and partnerships with Intel and Samsung.
THESE are the topics that are engaging, complex, fun and intriguing. And, they are the source of value for ENZC. If the IP is not strong, there is no there there, and the price is too high. If the IP does have value, ENZC stock price is waaaaaaaaay undervalued.
ITV-1's worldwide potential market is mostly outside parameters of FDA
https://en.wikipedia.org/wiki/List_of_countries_by_HIV/AIDS_adult_prevalence_rate
And, I see a VERRRRRY carefully worded phrase: "Drugs for sale in US", "without FDA review and approval"
Duh....the answer is zero. No kidding. But, if EMA approves, then the FDA will review in an expedited manner. No guarantee, but it would look good with EMA approval greasing the skids.
I've address price issue, but here we go again.
Price in Oct 2020 was $0.0001
Price in early 2021 was as high as $0.829
Price currently is around $0.08
Is price up 80,000% since merger? Yes
Is price down from peak? Yes
15 trading days prior to peak, the price was $0.11
Two months after peak, price was $0.15.
We can all agree that there was a brief period when pricing got a little crazy. But we can also agree that since merger, things are up - BIG TIME.
https://translate.google.com/?sl=en&tl=bg&text=Good%20Morning!&op=translate
Perhaps the filings are difficult to read
after key points are translated into "ulgarian-Bay"...
Investors are sadly being misled, by:
1) a weird focus on stock movements that happened pre-merger and assuming they are dispositive
2) no focus on the price increase since the merger - which completely refutes the dumping issue
3) completely ignoring the IP issue WHICH is the main point and store of value for ENZC
I will grant that IF there is no value in the IP, distribution agreements, partnerships etc, then ENZC is overpriced. If there IS INDEED value there, ENZC is wildly undervalued.
Follow on request regarding EMA approval
Need some data help, please.
Direct Phase 2 FDA won't be coming, since they are (as of now) not pursuing FDA testing in the conventional way. They are pursuing EMA approval (and, I guess, getting reciprocal FDA approval that way).
I vaguely recall that the company announced EMA progress at some time. Can someone help with a link?
https://translate.google.com/?sl=en&tl=bg&text=Perhaps%20a%20Bulgarian%3F%20(there%20are%20so%20many%20on%20this%20board...)&op=translate
Why be optimistic on ENZC?
Just one bit of IP - to review the ITV-1 drug and ENZC's history with the drug.
When a drug is approved by the EMA, after completing the Clinical Trials, ENZC would submit a validation order as part of the permitting process. Once the validation order is approved, then the EMA issues a PERMIT to sell the treatment in the countries accepting EMA approved drugs. Because there is a reciprocal agreement between the FDA and EMA the results of the clinical trials would be accepted by the FDA. Whether or not the FDA would issue permit to sell in the US, is up in the air. But with the EMA permit, most of the rest of the world will accept the treatment. Almost half of the worlds HIV cases are in Africa.
I have to believe that the purpose of the reciprocal treaty with the EMA was seamlessness - otherwise why have the treaty?
The concept of a “redo” is based on the following: The Bulgarian drug administration (under which the old trials were being conducted) joined the EMA after the validation order was produced for the old BDA clinical trial. It was not manufactured correctly in the US, which is why, in my opinion, the manufacturing has been moved to Bulgaria.
If the ITV-1 treatment passed for the BDA it only seems logical that it will pass the EMA.
OK, answer this:
How much float increased before merger? (when price was $0.0001) (Answer = approx. 80% prior)
How much dilution has there been since then? (answer = zero)
How much has float increased in last 6 months (answer - 25 million or < 1% of outstanding)?
How much potential float can happen? (answer 4%)
How much has the price risen since the merger? (answer = 78,000%)
How much will price rise if ANY of the IP is as good as the optimists think? (Answer = 100x or more, maybe 1000x)
Here's the talk you asked for.
Lazy analysts cherry picking a time frame. If anyone wants to pick a positive start, go with Oct 2020, when the price was $0.0001 - 78,000% improvement. If you pick the highest point, yes, there has been a loss.
Why was the stock so high then? You know....so does everyone else. Buyers got excited with the merger and all the good news and overbid the stock up to $0.95. Since then, it's been drifting down some.
Can we acknowledge that both camps are correct? If you pick the lowest price, performance looks terrific. If you pick the highest price, it looks terrible.
What does a smart investor do?
Understand that ENZC is a pre-revenue drug company. It's value is the potential of the products and the value of the intellectual property.
If you think the IP is worthless, then those who are pessimistic are correct. If you think the IP is solid and valuable, then the optimists are correct (and the stock is WILDLY undervalued - 100x-1000x undervalued). Looking at snippets of time is just lazy - especially since this is a pre-revenue stock.
Look at the posts that talk about the IP of ENZC and judge for yourself why there is value there.
Note that there’s zero talk of dilution (because there isn’t any!)
Also, no addressing of WHEN float increased, AND what happened to price.
Old news.
Most of float increase happened pre merger, when price was $0.0001.
By your own numbers, float was in the 1.7-1.8m range at time of merger.
Since merger:
Float up roughly 25-30% (normal and natural maturing)
Price up 78,000%
Dilution = absolutely ZERO.
AND, float cannot rise much more.
If you find it hard to read a “Wall of Text” (I do, too)
Just know that there are a few thing to keep in mind that refute almost everything. Since the BioClonetics merger forming ENZC,
1)there’s been zero dilution
2) 80+% of float increase happened when price was >$0.001, and was caused by the settling of old debt, whose shares were sold directly into the market
3) price is up 78,000%
4) tons of announcements with new partners, products and new IP
Dobro utro, my friend.
Are you kidding me?
This is all overfluffed (and frankly weird) and any substantial point has been refuted over and over and over.
Example? There have been 100s of posts, some from me and most from others, dealing with the fake dilution issue. A new disclosure came out on March 31, 2022 completely vindicating those who said no dilution. There’s been ZERO change in outstanding shares since at least Oct. 2020. But “cut-and-pasters” won’t even engage in substantial discussion.
Virtually every other issue has been debunked in the same manner too.
All fluff, or has been refuted.
Certainly the fake dilution issue has been put to bed.
New news is no dilution
New news is little float increase in past 12-18 months.
New news is pre-revenue company shortly to have revenue.
New news is new alliances, new patent filings, new distributorships, etc.
Dobro utro!
I’m glad we’ve finally put the fake dilution issue to bed.
Now, the Float.
Most of the previous increase in the float happened when the price was less than $0.001 and the market cap was >$25 million, for most, a lot less.
Absent dilution, which we all seem to agree hasn’t happened, math tells us the limit to the float increase is tight.
Again, focusing on the small stuff.
If the IP has no value, ENZC is overvalued. If the IP has value, ENZC us 100x or 1000x more valuable.
The focus should be: does ENZC have that value? No promises, but the outlook is terrific.
My response is simple:
Small changes in price don’t matter to me much. ENZC is a pre-revenue drug development company. Any value the company has is based on projections, not discounted cash flow.
If the intellectual property of ENZC isn’t valid, the stock is overpriced. But, if the IP is valid, the stock is wildly underpriced.
The company only has to hit on ITV-1…….or…….monoclonal antibodies……or……the MS drug…..or……the AI……or…….IPF Immune……or …..something else.
I can’t 100% say that there will be a hit, but, in my opinion, the odds are terrific. Then, the stock will soar.
Sorry for the delay in responding.
Check out post 145990
The key to remember is that there is no dilution. None since Oct 2020 (when the price was $0.0001)
So, if no dilution (which is the MUCH larger issue) what about float?
There are about 2.2 billion Unrestricted Shares, with Restricted shares totaling about only 400+ million (as of September 2021). So, that’s the max that can mature. Looking at the new disclosure, I see an additional 25 million that moved from Restricted to Unrestricted. Probably natural maturation. Float increased by 1% between Sept/21 and EOY/21.
The 300+ million held by officers and directors is unchanged. Almost all other issued shares have aged and are free floating right now. AND, the most did so when the stock was under a penny.
The only shares still restricted that arent accounted for are shares held by officers, shares tied up in litigation. 70 million of those restricted shares are the subject of the Savov litigation. In my opinion, the restrictions on those shares will NEVER be lifted. Using math, that means less than 100 million shares (less than 4%) are even available to mature and add to the float.
This was covered in post 145990 and originally in 145343
Looking at the new disclosure, I see an additional 25 million that moved from Restricted to Unrestricted, looks like natural maturation. Float increased by 1% between Sept/21 and EOY/21. But since there are no new shares issued (no dilution), that means that the available Restricted shares is reduced by that 25 million.
Looks to me like the Float situation is a non-issue.
145343:
Maturing stocks are a normal and natural process.
There are about 2.2 billion Unrestricted Shares, with Restricted shares are only 400+ million, of which 300+ million are held by officers and directors. Almost all other issued shares have aged and are free floating right now.
The only shares still restricted that arent accounted for are shares held by officers, shares tied up in litigation.
70 million of those restricted shares are the subject of the Savov litigation. In my opinion, the restrictions on those shares will NEVER be lifted. Using math, that means less than 100 million shares (less than 4%) are even available to mature and add to the float.
CHERVENO CHERVENO CHERVENO CHERVENO CHERVENO CHERVENO CHERVENO CHERVENO CHERVENO CHERVENO CHERVENO........
Spectacular analysis, if I do say so.
Low volume = people digesting
Me too, there is lots there....
A followup look at Restricted Shares and Float
in light of today's disclosure
Previously, I wrote: "There are about 2.2 billion Unrestricted Shares, with Restricted shares are only 400+ million, of which 300+ million are held by officers and directors. Almost all other issued shares have aged and are free floating right now. The only shares still restricted that arent accounted for are shares held by officers, shares tied up in litigation.
70 million of those restricted shares are the subject of the Savov litigation. In my opinion, the restrictions on those shares will NEVER be lifted. Using math, that means less than 100 million shares (less than 4%) are even available to mature and add to the float."
Looking at the new disclosure, I see an additional 25 million that moved from Restricted to Unrestricted, looks like natural maturation. Float increased by 1% between Sept/21 and EOY/21. But since there are no new shares issued (no dilution), that means that the available Restricted shares is reduced by that 25 million.
Looks to me like the Float situation is a non-issue.
OTC filing is out! No new shares issued = no dilution! No insider selling, they clearly believe in the company. In my opinion, there is zero basis to claim a “selling scam”, “pump and dump” or any other nefarious conspiracy. This filing clearly shows those concerns to be baseless.
I appreciate that.
It just saddens me that some are focussed on the technical smaller issues (and I say this with respect), like the analysis of small hour-by-hour or minute-by-minute shifts.
There are investors out there who are dancing on the price minute-by-minute. There are those to try and eek out a $0.001 profit on a ton of trades. If they want to trade ENZC, and squeeze out small trading profits, more power to them. Some like to focus on 1% here, -4% there.
That being said, it would be great to see you develop your hypothesis that there may be manipulation. My eyes don't see it, but I could be wrong. Please expound....
But, I find myself thinking that for myself and most investors, looking at the big picture, It does not really matter.. (which you mentioned)
ENZC may be sitting on world-changing drugs and AI and other technology. If all these things fail, the price of $0.08 is wildly overpriced and everyone will lose out. But, if any one of these things hit, $0.08 is an absolute bargain, we will be looking at a massive improvement in price. As you mentioned, the patents alone look fabulous.
That's the nature of drug development companies. It's kind of like a lotto ticket(s), BUT it's not all chance, humans are directing things.
If ITV-1 becomes successful, or the IPF spray or the AI, or the MS drug, or the monoclonals, etc. all the little stuff will not matter and the stock price will go BOOM.
We do need the audit, and I am disappointed
that it's not out yet.
Audited results are indeed important. Hopefully, they will be out soon. Given the track record of ENZC giving out dates, it's hard to be optimistic that it will happen tomorrow. Hope I am wrong.
Can we be honest?
.....and look for common ground?
ENZC is an exciting company, with a crazy number of cool patents, key industry partnerships and a massive potential future. Clearly, you (and others) feel a bit differently.
But, ENZC is a drug development company. That's not a normal "look at key revenue and P/E rations and determine a price" kind of stock. Any one particular drug being developed has an element of risk; Investors are sort of betting on big things happening, but the probability of that drug being wildly successful is low. With those parameters, it's sometimes hard to price.
ENZC does have some positive mitigating factors, the biggest one is that it's expanding on many fronts. ITV-1, the AI, IPF Immune, monoclonal antibodies, the MS drug (and I probably missed a few).
It's true that the price in Oct 2020 was $0.0001. It's also true that the price was as high as $0.829 (and yes, there was a intra-day trade on that day as high as $0.958) Using $0.08 as the base, the price is up 80,000% from Oct 2020, and down 73% from that closing high (and yes down 87% from that one weird intra-day trade).
Wow, a non-revenue drug development company has volatility. Like that's never happened...sheesh.
Also, a new publicly traded company with a management team who has little public company experience makes a few small mistakes (or ill advised tweets). Again, like THAT's never happened....eyes rolling
The more important issue for investors is: What is the likelihood that one or more of the company's initiatives will be successful? And if so, HOW successful? That is not an issue of the date of the filing of an audit, or a mis-worded PR. It's much larger.
- Is there success in the trials to date on ITV-1?
- Does the market accept IPF Immune?
- Is there outside validation (ie. partnerships) that indicate knowledgeable people think ENZC has something special?
- Are the other drugs/products/partnerships in the pipeline?
THAT is why I am bullish on ENZC!
Hey, we agree!
(sort of).
There is so much unfounded innuendo on this board - on all topics. CC seems like a good dude, and frankly, valuing a drug development company is fairly non-standard. (It's not like a retail store).
If anyone has evidence of nefariousness, report to authorities. But, if anyone is just posting crap for crap's sake, then it's clear that the innuendo is focussed on artificially driving the price down, not on real concern.
If there's nothing there, then stop airing weird accusations on this board, when there is nothing to back it.
Any CEO has fiduciary responsibility to shareholders.
Who cares who he "likes" or "dislikes"! Sheesh, sounds like a bad soap opera or a disgruntled ex-girlfriend....
The key is whether any CEO acts on behalf of all shareholders is to look at key evidence.
- Is the stock price holding up? That helps ALL us shareholders. Since merger, price up 80,000%.
- Are there shares issued diluting the existing shareholders? No new shares since merger, back in Oct 2020
Need some data help, please.
Phase 2 FDA won't be coming, since they are (as of now) not pursuing FDA testing.
ENZC is pursuing EMA approval (and, I guess, getting reciprocal FDA approval that way).
I vaguely recall that the company announced EMA progress at some time. Can someone help? Perhaps a Bulgarian? (there are so many on this board...)
Holy crap, I missed this. - Patent pending for MS treatment?
On January 19, 2021 the Company announced the receipt for the Multiple Sclerosis Patent Application.
https://www.biospace.com/article/releases/enzolytics-inc-receives-official-filing-receipt-for-multiple-sclerosis-patent-application/
What? I missed this? Embarrassed that we are not talking about this more.
Or, a 80,000% gain.
AND all the evidence I mentioned earlier.
To-may-to, to-mah-to
https://translate.google.com/?sl=en&tl=bg&text=love%20you%2C%20man%0A&op=translate. ;)
Regarding float.
Less than 100 million shares (less than 4%) are even available to mature and add to the float.
We Americans and Bulgarians can all agree that this is lots of yelling and stomping for 4% (at the max)
Dilution has not happened since Oct 2020, when the share price was $0.0001
Not Double 0 One, Triple 0 One. At that time, 1 billion shares = $100,000. The entire market cap of the company was approx. $270,000.
So, the theory is that since the shares were increased when the price was $0.0001 and no new shares have been issued AND the price has increased 800 times. (80,000%), that this is a problem?
Laughable.
Float vs. Dilution -
Let's look at Restricted Shares vs. Unrestricted Shares:
Maturing stocks are a normal and natural process. This makes the float increase slightly, but there is just not much room to increase the float
There are about 2.2 billion Unrestricted Shares, with Restricted shares are only 400+ million, of which 300+ million are held by officers and directors. Almost all other issued shares have aged and are free floating right now.
The only shares still restricted that arent accounted for are shares held by officers, shares tied up in litigation.
70 million of those restricted shares are the subject of the Savov litigation. Most likely, the restrictions on the Savov shares will NEVER be lifted. Using math, that means less than 100 million shares (less than 4%) are even available to mature and add to the float.
DEBUNKED!!!!!
No one, not even your Bulgarian authorities, have published any info on "investigations"
If anyone have filings/announcements etc. of any investigations, publish them.
It's called "Painting the Tape"
It is to laugh.
ENZC is being criticized (yes, criticized!) for putting out PR's. No, I am not kidding - who said that Bulgarians don't have a sense of humor?
Most investors WANT their companies to put out press releases and show everyone how they are doing.
ENZC is a drug development company. Revenue just starting soon.
In the past year, we have seen ENZC:
1) Produce ITV-1 for Africa and clinical trials
2) Produce IPF Immune for distribution in the US
3) Conduct trials at University of Strasbourg. Animal trials on France that are due soon.
4) Create a new distributorship in South America with RobustoMed
5) File a minimum of 18 new patents since Nov 2020
6) Develop AI
7) Do a joint release White paper with Intel
8) Do a Press Release with Samsung
9) Sold a distributorship - will get 1/2 ownership of Pharma plant in Bulgaria when permit is issued.
10) Started clinical trials in EMA
Pretty solid list of accomplishments for a drug development company.
15 million traded shares - wow. Something's happening. Clearly not a mass sell off, the price would have tanked, instead of being down only 1-2%.
I wish I knew, but that is solid support. Something's up.
Tangible, clear progress:
Waaaaaaaaaay better than your average drug development company,
- There are 2 hospitals in the absolute heart of the HIV epidemic who want to move forward with ENZC.
- Those hospitals are looking to treat up to 30,000 patients!
- IPF Immune has been announced to hit the market, I think this week we should see good news.
This is seriously good stuff - based on PR's from the company. Much better to look at OTC filings, real financial analysis and tangible PR from ENZC.